List of Excipients in Branded Drug METOLAZONE

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Lannett Company Inc	METOLAZONE	metolazone	0527-2215	CELLULOSE, MICROCRYSTALLINE
Lannett Company Inc	METOLAZONE	metolazone	0527-2215	D&C RED NO. 27
Lannett Company Inc	METOLAZONE	metolazone	0527-2215	FD&C BLUE NO. 1
Lannett Company Inc	METOLAZONE	metolazone	0527-2215	FD&C RED NO. 40
Lannett Company Inc	METOLAZONE	metolazone	0527-2215	MAGNESIUM STEARATE

Generic Drugs Containing METOLAZONE

Company	Ingredient	NDC	Excipient
Sandoz Inc	metolazone	0185-5050	CELLULOSE, MICROCRYSTALLINE
Sandoz Inc	metolazone	0185-5050	D&C RED NO. 30
Sandoz Inc	metolazone	0185-5050	FD&C BLUE NO. 2
Sandoz Inc	metolazone	0185-5050	MAGNESIUM STEARATE
Sandoz Inc	metolazone	0185-5050	SILICON DIOXIDE

What are the Most Frequently-Used Excipients in METOLAZONE?

# Of NDCs	Excipient
38	CELLULOSE, MICROCRYSTALLINE
3	D&C RED NO. 27
16	D&C RED NO. 30
1	D&C YELLOW NO. 10
1	FD&C BLUE NO. 1

Metolazone Excipient Strategy and Commercial Opportunities

Last updated: September 16, 2026

Metolazone is a mature, low-cost thiazide-like diuretic with no meaningful composition-of-matter exclusivity in major markets. Commercial value is concentrated in reliable generic supply, tablet robustness, dose flexibility, and differentiated oral liquid or low-dose products. Excipient selection should prioritize content uniformity, dissolution consistency, moisture control, and compatibility with lactose-sensitive or dysphagia-prone patients. The strongest opportunities are generic lifecycle improvements rather than new chemical-entity patent positions.

What is the commercial and regulatory status of metolazone?

Metolazone is an oral quinazoline sulfonamide diuretic approved for edema associated with congestive heart failure and renal disease, and for hypertension. It is commonly used with loop diuretics in patients with difficult-to-control fluid retention. U.S. tablet strengths generally include 2.5 mg, 5 mg, and 10 mg. [1]

Attribute	Metolazone position
Drug class	Thiazide-like diuretic
Common U.S. strengths	2.5 mg, 5 mg, 10 mg
Typical dosage form	Immediate-release tablet
Primary U.S. brand	Zaroxolyn
U.S. innovator	Originally approved for Pennwalt, later associated with other commercial owners
Current market structure	Generic-dominated
FDA pathway for new generic	ANDA under section 505(j)
Biosimilar relevance	None; metolazone is a small molecule
Orange Book exclusivity risk	No material remaining NCE or pediatric exclusivity
Main commercial barriers	Scale economics, quality consistency, supply reliability, ANDA approval

Metolazone is also marketed outside the United States under local brand and generic names. Product availability and approved strengths vary by country.

The FDA label identifies metolazone tablets as immediate-release oral products. The drug is absorbed from the gastrointestinal tract, has a relatively long duration of diuretic action, and is frequently administered once daily. [1] The clinical product is therefore suitable for conventional direct-compression or wet-granulation tablet platforms, subject to formulation-specific dissolution and content-uniformity performance.

What patents protect metolazone?

The original metolazone patent estate is expired. The active ingredient has been available for decades, and multiple generic manufacturers have marketed metolazone tablets. No commercially significant U.S. composition-of-matter barrier remains.

How strong is the metolazone patent estate?

Patent category	Current commercial significance
Composition-of-matter patents	Expired
Original therapeutic-use patents	Expired or commercially irrelevant
Immediate-release tablet patents	No meaningful blocking estate identified for the mature generic market
Manufacturing-process patents	Potentially relevant only if a supplier uses a proprietary process
Formulation patents	Possible for a new product, but no established barrier around conventional tablets
Device or delivery patents	Limited relevance because the established product is an oral tablet
Orphan-drug exclusivity	Not applicable to standard metolazone products
Biosimilar exclusivity	Not applicable

A new applicant could still seek patent protection for a novel formulation, salt, particle-size distribution, controlled-release system, taste-masked liquid, or combination product. Such patents would protect the new product only if the claims are technically differentiated and survive validity and infringement challenges. They would not restore exclusivity over conventional metolazone tablets.

When does metolazone lose exclusivity?

Metolazone lost its principal exclusivity decades ago. Conventional generic entry is already established in the United States and other regulated markets.

The relevant commercial question is not loss of exclusivity but whether a new entrant can achieve a sustainable cost, quality, or product-differentiation advantage.

What is the Orange Book status of metolazone?

FDA Orange Book records should be reviewed by product reference listed drug and strength because patent and exclusivity data are product-specific. The mature generic market indicates that no listed patent has prevented ANDA approvals for standard metolazone tablets. [2]

For a new ANDA applicant, the likely pathway is:

1. Identify the reference listed drug.
2. Match strength, dosage form, route, and labeling.
3. Demonstrate pharmaceutical equivalence.
4. Demonstrate bioequivalence under the applicable FDA standard.
5. Address any current Orange Book patent certifications, if listed.
6. Submit manufacturing, stability, dissolution, and quality data.

A Paragraph IV certification would be relevant only if an applicable patent were listed against the selected reference product. For a conventional immediate-release metolazone tablet, Paragraph IV litigation risk is expected to be low because the central patent estate is old and the market already includes multiple generic products.

What excipients are used in metolazone tablets?

Metolazone excipients vary by manufacturer, strength, compression platform, and market. Public product labels and DailyMed entries show that metolazone tablets may use conventional excipients such as lactose, starch, povidone, crospovidone or other disintegrants, colloidal silicon dioxide, and magnesium stearate. Exact compositions must be confirmed from the label of the target product. [3,4]

What excipient functions matter most?

Excipient function	Commercial objective	Candidate classes
Diluent	Achieve tablet mass and dose uniformity at 2.5 mg	Lactose, microcrystalline cellulose, dibasic calcium phosphate
Binder	Improve granule and tablet strength	Povidone, copovidone, pregelatinized starch
Disintegrant	Support prompt release	Crospovidone, croscarmellose sodium, sodium starch glycolate
Lubricant	Prevent sticking and ejection defects	Magnesium stearate, sodium stearyl fumarate
Glidant	Improve powder flow	Colloidal silicon dioxide
Moisture-control aid	Improve stability and process reproducibility	Low-moisture excipient grades, protective packaging
Taste modifier	Improve liquid or orally disintegrating products	Sweeteners, flavors, ion-exchange resins
Suspending system	Support oral liquid uniformity	Xanthan gum, cellulose derivatives, structured vehicles

The 2.5 mg strength presents the greatest formulation challenge. The active dose is low relative to tablet mass, so blending efficiency and segregation control are central quality risks. A formulation can meet assay limits while still experiencing unacceptable blend variability if the active ingredient has a different particle-size distribution or bulk density from the principal diluent.

How should a metolazone excipient strategy be designed?

A robust strategy should use a platform formulation across the 2.5 mg, 5 mg, and 10 mg strengths where possible. The platform reduces development cost, simplifies scale-up, and supports a common dissolution and stability package.

Direct compression versus wet granulation

Direct compression is attractive for a mature generic product because it reduces unit operations and manufacturing cost. It requires:

• Consistent active-particle-size distribution.
• Adequate flow at low drug loading.
• Low segregation tendency.
• Reliable tablet tensile strength.
• Controlled lubricant blending.
• Stable dissolution after storage.

Wet granulation is more forgiving when metolazone has poor flow, poor compactability, or segregation risk. It can improve content uniformity and tablet mechanical strength, but it introduces additional process variables, including granulation endpoint, drying temperature, residual moisture, and granule-size distribution.

A practical development sequence is to screen direct compression first, then use dry or wet granulation if low-dose uniformity, friability, or dissolution cannot be controlled.

Lactose-containing and lactose-free platforms

Lactose is a cost-effective diluent with strong tableting performance, but lactose-free products can address patients with lactose sensitivity and simplify positioning in selected markets. Microcrystalline cellulose, mannitol, starch, and dibasic calcium phosphate are possible alternatives.

A lactose-free formulation may have higher material cost and different compactability or dissolution behavior. Its commercial value is greatest when combined with another differentiator, such as a low-dose tablet, scored design, or broader institutional purchasing requirement.

Lubrication control

Magnesium stearate is widely used but can slow dissolution when overmixed or used at excessive levels. The risk is material for a low-dose immediate-release tablet because dissolution performance can be sensitive to hydrophobic coating of particles.

Development should control:

• Lubricant concentration.
• Lubrication time.
• Blender fill level.
• Shear exposure.
• Granule surface area.
• Tablet porosity.

Sodium stearyl fumarate can be evaluated where a less hydrophobic lubrication profile or improved processing performance is needed, although its cost and supplier availability may differ.

Moisture and packaging

The appropriate packaging strategy depends on stability data rather than on excipient selection alone. High-barrier blister packaging or a desiccant-containing bottle may be justified if moisture affects tablet hardness, dissolution, assay, or impurity formation.

The commercial trade-off is straightforward:

Packaging option	Advantage	Limitation
HDPE bottle	Lowest cost and simple filling	Greater exposure to repeated moisture ingress
Desiccant bottle	Improved moisture protection	Higher packaging cost and component complexity
Alu-Alu blister	Strong barrier and unit-dose presentation	Higher material and packaging-line cost
PVC/PVdC blister	Balanced barrier and cost	Less protective than aluminum systems

What formulation patents could protect a new metolazone product?

Conventional excipient combinations are unlikely to support strong patent protection unless they produce an unexpected technical result. More defensible claims could focus on measurable product attributes or specialized delivery systems.

Potential formulation opportunities

Low-dose content-uniformity platform

A formulation designed specifically for 2.5 mg tablets could claim a narrow particle-size range, carrier architecture, ordered mixing process, or blend-uniformity result. The strongest patent position would require data showing a technical advantage over conventional formulations.

Orally disintegrating tablet

An orally disintegrating metolazone product could target patients with dysphagia, geriatric patients, or home-care settings. Candidate excipients include mannitol, crospovidone, low-substituted hydroxypropyl cellulose, and taste-masking agents.

The principal challenges are the bitter or unpleasant taste of the active ingredient, mechanical fragility, moisture sensitivity, and dose uniformity at low drug loading.

Oral liquid

A ready-to-use oral solution or suspension could address patients unable to swallow tablets and could support dose titration below standard tablet strengths. The product would require control of:

• Chemical stability in the liquid vehicle.
• Uniformity throughout shelf life.
• Microbial quality.
• Preservative effectiveness, if applicable.
• Sedimentation and redispersibility for a suspension.
• Taste and dosing-device accuracy.

A metolazone suspension may be more practical than a true solution if solubility limits prevent a stable, commercially useful concentration. A suspension would need robust shaking instructions and validated dose uniformity throughout container use.

Modified release

Modified-release metolazone could seek to reduce peak-related tolerability issues or extend diuretic exposure. The opportunity is technically less attractive because metolazone is commonly used for predictable daily diuresis and often combined with other diuretics. Development would also require additional clinical and bioequivalence work.

Combination products

A fixed-dose combination with a loop diuretic could reduce pill burden, but the clinical dosing flexibility of each component is a major obstacle. Loop diuretics and metolazone are often titrated independently, particularly in heart failure and renal disease. A combination product could therefore face limited prescriber adoption unless it targets a narrow, stable regimen.

What generic entry risks exist for metolazone?

The main risks are commercial and operational rather than patent-based.

Manufacturing and quality risks

Low-dose metolazone products require tight control of:

• Active-material assay and particle size.
• Blend uniformity.
• Tablet weight variation.
• Compression force.
• Dissolution.
• Impurity profile.
• Stability under humidity stress.
• Cross-contamination during shared manufacturing.

The low dose increases the importance of validated sampling plans. Conventional thief sampling can miss localized segregation, particularly when the active has a different density from the diluent.

Supply-chain risks

Metolazone is a small-volume generic product compared with high-volume antihypertensives. Suppliers may face limited API scale, fewer qualified sources, and weak economies of scale. A second API source can improve continuity but may trigger comparability work involving particle size, polymorphic form, residual solvents, elemental impurities, and dissolution.

Commercial risks

The product may face:

• Low reimbursement ceilings.
• Institutional purchasing pressure.
• Multiple approved generic competitors.
• Retail substitution.
• Low allowable price increases.
• Inventory volatility during competitor shortages.
• Limited return on an expensive reformulation.

A new entrant needs either a low-cost manufacturing model or a differentiated presentation with a clear clinical or dispensing benefit.

Which companies are challenging metolazone products?

The conventional U.S. market is generic and has historically included multiple manufacturers and labelers, including products distributed under generic labels and by companies such as ANI Pharmaceuticals and other approved generic suppliers. Manufacturer participation can change as products are discontinued, transferred, or relabeled. FDA Drugs@FDA, the Orange Book, and current DailyMed records are the relevant sources for active product status. [2-4]

No biosimilar competitors are relevant because metolazone is a chemically synthesized small molecule. Competition occurs through ANDAs, authorized generic arrangements, contract manufacturing, and distributor-labeler relationships.

What licensing deals and partnerships are commercially relevant?

Metolazone has limited licensing value as a conventional tablet because the active ingredient is old and widely available. Potential transaction value exists in:

• Regional rights for a differentiated oral liquid.
• Contract manufacturing of low-dose tablets.
• Supply agreements for hospital or long-term-care channels.
• Co-development of an orally disintegrating product.
• Acquisition of an approved ANDA with established commercial history.
• API supply and dual-source qualification.

A licensing deal based only on standard 2.5 mg, 5 mg, or 10 mg tablets would likely depend on manufacturing cost, approved market access, and supply reliability rather than patent exclusivity.

How does metolazone compare with competing diuretics?

Product	Main commercial distinction	Excipient opportunity
Metolazone	Thiazide-like diuretic used for edema and hypertension; often paired with loop diuretics	Low-dose uniformity, liquid, ODT, stable generic supply
Hydrochlorothiazide	High-volume thiazide with extensive generic competition	Limited margin; broad tablet and combination competition
Chlorthalidone	Long-acting thiazide-like diuretic	Dose flexibility and modified-release concepts, but clinical positioning differs
Indapamide	Thiazide-like agent with immediate- and modified-release products in some markets	Modified-release and low-dose formulation opportunities
Furosemide	Loop diuretic with broad dosage-form availability	Oral solution, injectable supply, and combination strategies

Metolazone’s strongest clinical differentiation is its use in combination with loop diuretics, especially where additional natriuresis is required. Its commercial weakness is the small market size relative to hydrochlorothiazide and furosemide.

What is the revenue exposure for a metolazone manufacturer?

Revenue exposure is usually modest at the product level but can be strategically important for a generic portfolio. Product economics depend on:

• Annual prescription volume.
• Strength mix, particularly the 2.5 mg tablet.
• Wholesale acquisition price.
• Manufacturing yield.
• API cost.
• Packaging format.
• Contract terms.
• Number of competitors.
• Shortage-driven price movement.

The 2.5 mg strength may have higher development value because it supports titration and may face fewer direct competitors in some markets. The 5 mg and 10 mg strengths generally provide manufacturing and portfolio continuity rather than strong pricing power.

What generic launch scenarios are most realistic?

Low-cost conventional tablet

This is the lowest-risk route but has limited differentiation. Success depends on efficient manufacturing, reliable API sourcing, and an established distribution channel.

Lactose-free or excipient-reduced tablet

This can support a targeted label claim or institutional preference, but the commercial premium may be insufficient unless the product also improves supply reliability or addresses a documented procurement need.

Oral liquid or suspension

This has greater differentiation and can target dysphagia, pediatric specialty use where clinically appropriate, and dose titration. It also carries higher stability, microbiology, packaging, and regulatory risk.

Orally disintegrating tablet

This may support a branded-generic strategy. Taste masking, moisture protection, and tablet robustness determine feasibility.

Combination product

This has the highest clinical development and regulatory complexity. Independent dose titration limits the addressable market.

Key Takeaways

• Metolazone is a mature, generic-dominated small molecule with no meaningful remaining composition-of-matter exclusivity.
• Standard immediate-release tablets face low patent risk and high price competition.
• The principal formulation challenge is low-dose content uniformity, especially for the 2.5 mg strength.
• Direct compression should be evaluated first, with granulation used if flow, segregation, or compactability are inadequate.
• Lactose-free, orally disintegrating, and liquid products offer the clearest formulation differentiation.
• Modified-release and fixed-dose combination products have higher technical and clinical risk.
• Manufacturing reliability, dual-source API qualification, and dissolution consistency are more important than patent blocking for conventional generic entry.
• Licensing value is concentrated in differentiated dosage forms, regional rights, approved ANDAs, and dependable supply arrangements.
• Metolazone has no biosimilar risk because it is a chemically synthesized small molecule.
• A commercially viable launch requires either a low-cost supply model or a formulation that solves a specific dispensing or adherence problem.

FAQs

Can metolazone be formulated as an oral solution?

Yes, but chemical stability, solubility, taste, preservative control, and dose uniformity must be demonstrated. A suspension may be more practical than a true solution if the target concentration exceeds metolazone’s usable solubility.

Is lactose-free metolazone commercially attractive?

It can be attractive as a targeted generic product, especially where lactose sensitivity or excipient restrictions affect procurement. The opportunity is stronger when paired with improved packaging, supply reliability, or a low-dose presentation.

Does metolazone require a biosimilar application?

No. Metolazone is a small-molecule drug, so a new conventional product generally proceeds through an ANDA rather than the biosimilar pathway.

Would an extended-release metolazone product have strong patent value?

Potentially, but patent value would depend on a technically credible release mechanism, clinical utility, and data showing an advantage over immediate-release therapy. The development burden would be materially higher than for a standard generic tablet.

Which metolazone strength has the best commercial opportunity?

The 2.5 mg strength is the most technically and commercially differentiated because it supports dose titration and creates greater low-dose formulation demands. The 5 mg and 10 mg strengths remain important for portfolio completeness and physician prescribing continuity.

References

1. U.S. Food and Drug Administration. (2012). Zaroxolyn (metolazone) tablets prescribing information. FDA.
2. U.S. Food and Drug Administration. (n.d.). Approved drug products with therapeutic equivalence evaluations: Orange Book. FDA.
3. National Library of Medicine. (n.d.). DailyMed: Metolazone tablet drug labels. U.S. National Library of Medicine.
4. U.S. Food and Drug Administration. (n.d.). Drugs@FDA: FDA-approved drugs. FDA.